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Abstract
The objective of this work was to improve chemical and physical stability of the EC1 protein
derived from the extracellular domain of E-cadherin. In solution, the EC1 protein has been shown
to form a covalent dimer via a disulfide bond formation followed by physical aggregation and
precipitation. To improve solution stability of the EC1 protein, the thiol group of the Cys13
residue in EC1 was alkylated with iodoacetate, iodoacetamide, and maleimide-PEG-5000 to
produce thioether derivatives called EC1-IA, EC1-IN, and EC1-PEG. The physical and chemical
stabilities of the EC1 derivatives and the parent EC1 were evaluated at various pHs (3.0, 7.0, and
9.0) and temperatures (0, 3, 70 °C). The structural characteristics of each molecule were analyzed
by circular dichroism (CD) and fluorescence spectroscopy and the derivatives have similar
secondary structure as the parent EC1 protein at pH 7.0. Both EC1-IN and EC1-PEG derivatives
showed better chemical and physical stability profiles than did the parent EC1 at pH 7.0. EC1-
PEG had the best stability profile compared to EC1-IN and EC1 in solution under various
conditions.
Keywords
E-cadherin; EC1 domain; Pegylation; Thiol acetylation; Physical stability; Chemical stability
INTRODUCTION
E-cadherin is a calcium-binding glycoprotein found at the adherens junction of the
intercellular junctions of the intestinal mucosa (Zheng et al., 2006). It is one of the important
proteins that mediate cell-cell adhesion at the intercellular junctions. Modulation of cadherin
interactions at the intercellular junctions by cadherin peptides improves the delivery of
paracellular marker molecules (i.e., 14C-mannitol) and anticancer drugs (i.e., 3H-
daunomycin) through the blood-brain barrier (Kiptoo et al., 2011). The EC1 domain of E-
cadherin has an important role in the selectivity of homophilic E-cadherin interactions as
well as in the heterophilic interaction of E-cadherin with αEβ7 integrin to create cell-cell
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adhesion (Pokutta et al., 2008; Pokutta and Weis, 2007; Shiraishi et al., 2005; Zheng et al.,
2006). To study the biological function of the EC1 domain to modulate cell-cell adhesion at
the intercellular junctions of the intestinal mucosa, we expressed the recombinant human
EC1 protein. Unfortunately, the EC1 protein is unstable during storage (i.e., 4 weeks at 4
°C) after purification. It produces a covalent dimer (EC1-s-s-EC1) via an intermolecular
disulfide bond between the only Cys residue (Cys13) in the monomer, and the formation of
a covalent dimer induces the generation of oligomers and precipitation (Makagiansar et al.,
2002b; Trivedi et al., 2009). The presence of the covalent dimer and physical oligomers has
been characterized using SDS-PAGE and size-exclusion chromatography (SEC) as well as
by monitoring changes in its far UV circular dichroism (CD) spectra and intrinsic
fluorescence emission spectra after storage at 4 °C. The presence of precipitates prevents
long-term storage and interferes with the study of the biological activity of EC1 as an
inhibitor of cell-cell adhesion. Therefore, it is necessary to find a suitable method to improve
the storage stability of this protein for its use in future biological activity evaluations in
inhibiting cell-cell adhesion.
Accelerated stability studies at different pH values (3.0, 7.0, and 9.0) and temperatures (37
°C and 70 °C) have shown that the EC1 protein also undergoes hydrolysis at the D93–P94
peptide bond (Trivedi et al., 2009). Molecular dynamics simulation studies have indicated
that the covalent dimer has a higher dynamic mobility than the monomer, thereby
contributing to the instability of the protein (Trivedi et al., 2009). The increased flexibility of
the EC1 dimer could explain the susceptibility of the D93P94 peptide bond to hydrolysis
and physical oligomerization. It is interesting to find that chemical and physical degradation
can be inhibited by addition of dithiothreitol (DTT) as a reducing agent to prevent the
formation of a covalent dimer. However, the presence of reducing agents (i.e., DTT or
glutathione) would be undesirable during biological activity studies (i.e., inhibition of cell-
cell adhesion) of EC1 since they may affect the results of the cell adhesion assays. Thus, an
alternative method is needed to stabilize the monomeric form of the EC1 protein so it can be
evaluated in biological assays and stored for long periods of time.
To eliminate the possibility of covalent dimerization of the EC1 protein, the thiol group of
the Cys13 residue in EC1 was alkylated to produce thioether derivatives called EC1-IA,
EC1-IN, and EC1-PEG (Fig. 1). To produce EC1-IA and EC1-IN, the thiol group of EC1
was reacted with iodoacetic acid and iodoacetamide, respectively; this method has been
extensively applied to modify protein (Dickens, 1933; Smythe, 1936). Next, the EC1 protein
was derivatized with polyethylene glycol-5000 (PEG5000) to prepare EC1-PEG by reacting
the Cys13 thiol group with the maleimide group on the PEG5000 (Bell et al., 2008; Colonna
et al., 2008). The physical and chemical stabilities of the EC1 derivatives were compared to
those of the parent EC1 and evaluated at various pHs (3.0, 7.0, and 9.0) and temperatures (0,
37, 70 °C). The structural characteristics of EC1 derivatives during the stability studies were
analyzed by circular dichroism (CD) and fluorescence spectroscopy (Trivedi et al., 2009).
The stability of both EC1-IN and EC1-PEG derivatives was better than that of the parent
EC1 at pH 7.0. Compared to EC1-IN and EC1, the EC1-PEG had the best stability profile
under various conditions.
EXPERIMENTAL METHODS
Production of EC1-IA and EC1-IN
The EC1 protein (M.W. = 11,628 Da) was expressed in E. coli and purified in the presence
of β-mercaptoethanol (BME) (Makagiansar et al., 2002a; Makagiansar et al., 2002B). The
EC1 protein (0.2 mg/mL) was reacted in the dark with iodoacetate or iodoacetamide (1.0
mM) for 4 h at pH 8.0 in a buffer containing 0.02 mM BME, 20 mM Tris, and 4.0 M
guanidine hydrochloride (Gdn.HCl). The completion of the reaction was monitored and
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confirmed by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry with
time-of-flight (TOF) detection. The alkylated EC1 (EC1-IA and EC1-IN) was refolded by
employing a stepwise dilution method in which the concentration of Gdn.HCl was reduced
from 4.0 M to 0.5 M with a 0.5 M decrease in each dilution step. The dilution step consists
of the addition of an appropriate volume of a buffer containing 20 mM Tris at pH 8.0,
followed by incubation at 4 °C for 8 h. When the Gdn.HCl concentration reached 0.5 M,
dialysis was performed with an 8-kD membrane to remove the Gdn.HCl, BME, and the
unreacted iodoacetate or iodoacetamide. Far UV CD spectroscopy was used to determine the
success of protein refolding.
Production of EC1-PEG
Maleimide-PEG (250 mg, MW = 5,000 Da, Sigma Chemical Co., St. Louis) was added to
50 mL of 20 mM Tris buffer at pH 8.0 containing 0.2 mg/mL of EC1 and 0.2 mM DTT. The
reaction mixture was incubated for 2 h at 22 °C followed by injection of 50 μL of the
solution to MALDI-TOF MS analysis. The remaining solution was concentrated to 10 mL
by passing it through a 10,000 Da cutoff membrane in an Amicon centrifuge tube and
centrifuging at 4000 × g. The concentrated solution was stored at 4 °C until it was purified
by SEC.
Three mL of the above concentrated solution was injected into a Superdex 200 size-
exclusion column with a mobile phase of 20 mM Tris buffer at pH 8.0 and a flow rate of 0.5
mL/min. The EC1-PEG conjugate, parent EC1, and the maleimide-PEG were detected as
separate peaks in the SEC chromatogram by their UV absorbance at 220 or 280 nm, and the
yield of EC1-PEG was 75%. The column volume was 150 mL, and the volume of each
collected fraction was 3.0 mL. The EC1-PEG fractions were pooled and concentrated to 7.5
mL. The concentration of EC1-PEG in this final solution was equal to 86 μM of EC1. Fifty
μL of this EC1-PEG solution was analyzed by MALDI-TOF. The remaining EC1-PEG was
used for chemical stability studies using high performance liquid chromatography (HPLC)
analysis and structural studies using far CD spectroscopy and intrinsic fluorescence emission
spectroscopy.
Chemical stability studies of EC1-IN and EC1-PEG
The EC1-IN and EC1-PEG proteins were dialyzed into pH 3.0, 7.0, and 9.0 buffers and
incubated at a concentration of 86 μM in sealed vials at 4, 37, and 70 °C for 4 h (Trivedi et
al., 2009). The buffers used were 100 mM phosphate for pH 3.0, 50 mM phosphate for pH
7.0, and 100 mM borate containing 0.08 M NaCl for pH 9.0. Samples were drawn at 0, 0.5,
1.0, 2.0, and 4.0 h and immediately stored at −70 °C until subsequent HPLC analysis was
performed. The HPLC was equipped with a C18 column (Varian Microsorb; pore-size: 300
Å; dimensions 250 × 4.6 mm) for separation of the analytes. The protein solution (25 μL)
was injected into the column and eluted at a rate of 1.0 mL/min. A gradient elution method
incorporating solvent A (94.9% double distilled water, 5% acetonitrile (ACN), and 0.1%
TFA) and solvent B (100% ACN) was used. The gradient elution followed the sequence 0%
to 45% B from 0.0 to 2.0 min, 45% to 51% B from 2.0 to 12.0 min, at 51% B from 12.0 to
17.0 min, 51% to 100% B from 17.0 to 19.0 min, at 100% B from 19.0 to 21.0 min, and
100% B back down to 0% B from 21.0 to 22.0 min. A Varian Prostar UV detector at a
wavelength of 220 nm was used to detect the proteins eluted from the column. MALDI-TOF
MS analysis was used to determine the molecular weight of any new peaks observed on the
HPLC chromatogram.
Physical stability studies
Physical stability studies of EC1-IN and EC1-PEG were performed by monitoring the far
UV CD spectra and the intrinsic fluorescence emission spectra at days 0, 14, and 28 of
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incubation at 4 °C and pH 3.0, 7.0 and 9.0. The concentrations and buffers used were the
same as described in the chemical stability studies section.
Far UV CD studies—The secondary structural changes of the EC1-IN or EC1-PEG
protein were analyzed by far UV CD spectroscopy with a Jasco spectropolarimeter (J-720)
equipped with a Peltier temperature controller by loading 300 μL of the protein into a sealed
CD cuvette with 0.1 cm pathlength (Derrick et al., 2004; Zheng et al., 2009a; Zheng et al.,
2009b). The protein CD spectrum was measured at 10 °C between 200 and 250 nm.
Triplicate spectra were obtained for EC1-IN or EC1-PEG, and the contribution of the buffer
was eliminated by subtracting the blank spectrum (containing buffer alone) from the
spectrum of protein in the same buffer. The same samples were also used for the thermal
unfolding studies by recording their CD spectra at every 5°C increase in temperature. The
temperature of the cuvette holder was increased from 10 °C to 65 °C at a rate of 15 °C/h.
The samples were equilibrated at the target temperature for 300 s before obtaining their
spectra. The entire procedure was repeated after 14 and 28 days for samples stored at pH
3.0, 7.0, and 9.0 at 4 °C. The ellipticity at 218 nm (used to monitor changes in the β-sheet
content) was plotted against the corresponding temperature, and a sigmoidal function was
used to fit the thermal unfolding curves using Origin 7.0 software. The midpoint of each
transition in the sigmoidal fit was defined as the thermal unfolding temperature (Tm).
Intrinsic fluorescence emission studies—Changes in the tertiary structure of EC1-IN
and EC1-PEG after 14 and 28 days incubation at 4 °C and different pH values (3.0, 7.0, or
9.0) were monitored using fluorescence spectroscopy and compared to the emission profile
on day 0. For each experiment, 90 μL of the protein (86 μM) was diluted to 0.9 mL with the
appropriate buffer and transferred to a quartz fluorescence cuvette. The protein was excited
at 295 nm (>95% Trp emission), and the fluorescence emission was observed between 305
and 405 nm using a PTI QuantaMaster spectrofluorometer (Rexroad et al., 2003; Zheng et
al., 2009a; Zheng et al., 2009b). Emission was set between 500,000 and 1,000,000 counts/
sec by adjusting the excitation and emission slits. The emission spectra were obtained in
triplicate, and the blank spectrum was subtracted from each of them. Thermal unfolding of
EC1-IN and EC1-PEG was studied at pH 3.0, 7.0, and 9.0 by increasing the temperature of
the cuvette chamber from 10 °C to 87.5 °C at a rate of 15 °C/h; the emission spectra were
recorded at every 2.5 °C increase in temperature. Each fluorescence emission spectrum
obtained was fitted to an extreme asymmetric peak function using the non-linear curve-
fitting wizard of Origin 7.0 software to obtain the wavelength of maximum emission. After
subtracting the blank emission signal from each spectrum, the wavelength of maximum
emission at each temperature point was plotted against the corresponding temperature. This
plot, which provided the thermal unfolding profile of the protein, was then fitted to a
sigmoidal function using Origin 7.0 software.
RESULTS
Alkylation of the thiol group of EC1
The alkylation of EC1 with iodoacetate and iodoacetamide (Fig. 1) produced the desired
EC1-IA and EC1-IN in quantitative yields with one band in an SDS PAGE gel and a single
peak on a reversed-phase HPLC C18 column. MALDI mass spectra showed the addition of
acetate and acetamide groups in EC1-IA (MW = 11,686.6 Da) and EC1-IN (MW = 11,685.3
Da), respectively. The reaction between Cys thiol of EC1 and maleimide-PEG produced
EC1-PEG in 75% yield, and the desired EC1-PEG was separated from the EC1 and PEG by
SEC. Using a C18 reversed-phase column, EC1-PEG showed a single peak at 8.1 min
compared to EC1 at 8.4 min and maleimide-PEG at 7.9 min. The MALDI spectrum of EC1-
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PEG showed a broad peak centered around MW of 16,927 due to a distribution of molecular
weights of the PEG group around 5,000 Da.
The CD spectra of EC1-IA and EC1-IN were compared with that of EC1. The EC1-IN
protein has a spectrum identical to that of EC1 at pH 7.0 with a minimum at 216 nm and
maxima at 235 and 205 nm (Fig. 2). However, the CD spectra of EC1-IA at various pH
values showed that this protein was not properly folded (data not shown); thus, it was not
investigated further for the stability studies. The secondary structure of EC1-IN is sensitive
to pH changes, indicated by the CD spectra of EC1-IN at pH 3.0, 7.0, and 9.0 (Fig. 2). The
minimum at 216 nm at pH 7.0 shifted to 210 nm at pH 3.0 and 9.0. Furthermore, the spectra
at pH 3.0 and 9.0 lack the maxima at 205 and 235 nm. These results indicate that EC1-IN
has a secondary structure similar to that of the parent EC1 at pH 7.0, but not at pH 3.0 and
9.0.
The CD spectra of EC1-PEG were compared to those of EC1 at pH 3.0, 7.0, and 9.0. At pH
3.0, a minor difference was observed between the spectra of the two proteins (Fig. 3A) in
which the spectrum of EC1-PEG had more pronounced positive and negative peaks at 235
nm and 216 nm, respectively. There was no difference between the spectra of EC1-PEG and
EC1 at pH 7.0 (Fig. 3B) and 9.0 (Fig. 3C), suggesting that the PEGylated protein maintains
its conformation.
Chemical stability comparison of EC1, EC1-IN, and EC1-PEG
The chemical stability of the EC1-IN protein was monitored by HPLC after incubation for 4
h at 4 °C and pH 3.0, 7.0, and 9.0. Under these conditions, there was no observable decrease
in the chromatographic peak of the EC1-IN protein and no appearance of a new peak for any
degradation product (data not shown). These results indicate that the EC1-IN protein is
stable upon incubation for 4 h at 4 °C at all three pH values.
The EC1-IN protein was also chemically stable for 4-h incubation at 37 °C and pH 3.0, 7.0,
and 9.0 (Fig. 4A) with no significant change in the area under the peak of EC1-IN and no
new peaks representing the degradation products. This result is in contrast to our previous
studies on EC1 in which EC1 was unstable during 4-h incubation at pH 7.0 and 9.0 at 37 °C
with the observed Asp93–Pro94 peptide bond hydrolysis product (Trivedi et al., 2009).
These results imply that the EC1-IN protein is more stable to hydrolytic cleavage than is the
parent EC1 protein at 37 °C.
The EC1-IN protein was also stable for 4 h at pH 7.0 and 9.0 at 70 °C (Fig. 4B), which is
more stable than the parent EC1 under these conditions. Previously, the EC1 protein was
shown to undergo Asp93–Pro94 peptide bond hydrolysis and precipitation under similar
conditions (Trivedi et al., 2009). Under pH 3.0 and 4-h incubation at 70 °C, however, a
significant decrease in the amount of EC1-IN (to 22%) was observed, followed by the
appearance a new peak with MW = 10,443.5 Da corresponding to the hydrolysis product at
the Asp93–Pro94 peptide bond (Fig. 4B). Moreover, at pH 3.0, the increase in the peak area
of the hydrolysis product did not correspond quantitatively to the decrease in the peak area
of the EC1-IN protein; this was due to the aggregation that leads to precipitation of the
protein.
The chemical stability of EC1-PEG at 70 °C was compared with that of EC1-IN and EC1 by
incubation at pH 3.0, 7.0, and 9.0 for 4 h (Fig. 5). At all three pH values studied, the amount
of EC1-PEG did not change substantially after incubation for 4 h at 70 °C. Moreover, no
new peaks appeared in the chromatograms. This suggests that, at high temperature, EC1-
PEG is stable to precipitation and to chemical degradation reactions such as peptide bond
hydrolysis. In contrast, the amount of EC1 remaining in solution was the lowest upon
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incubation at pH 3.0, followed by incubation at pH 7.0 and pH 9.0. The EC1-IN protein was
also more stable than the EC1 protein at pH 7.0 and 9.0; however, it was unstable at pH 3.0.
Physical stability comparison of EC1, EC1-IN, and EC1-PEG
Secondary structure studies of EC1 and EC1-IN using CD spectroscopy—The
effect on its physical stability of incubating EC1-IN at pH 3.0, 7.0 and 9.0 at 4 °C for up to
28 days was studied by observing changes in its CD spectra and comparing the data to the
CD spectra of the parent EC1 protein. At pH 3.0, the CD spectra of the EC1-IN protein did
not change after incubation for 14 days (Fig. 6A). The CD spectra of EC1, however,
changed from day 0 to day 14 with a shift in the minimum at 216 nm and disappearance of
the maxima at 235 and 205 nm (Fig. 6A), suggesting an increase in β-sheet character that
could be due to the formation of oligomers. The melting curve of EC1-IN was compared to
that of EC1 by monitoring the change in the CD signal at 218 nm (Fig. 7A). At pH 3.0, there
is a very small difference in the melting curve of EC1-IN after 14-day incubation, whereas a
dramatic change is detected in the melting curve of EC1 after 14-day incubation. These data
imply that EC1-IN does not undergo changes such as covalent dimerization or physical
oligomerization when incubated at 4 °C for 14 days as does EC1.
At pH 7.0, the CD spectra of EC1-IN protein did not change upon incubation for 0, 14, and
28 days at 4 °C (Fig. 6B). On the other hand, incubation of the EC1 protein under the same
conditions produced changes in the CD spectra after 28 days (data not shown). The melting
curves of EC1-IN after incubation for 0, 14, and 28 days did not change, but the melting
curves of the EC1 protein showed dramatic changes (Fig. 7B), suggesting that EC1-IN did
not undergo physical degradation upon incubation.
At pH 9.0, CD spectra of the EC1-IN protein after 14 and 28 days incubation showed a
dramatic shift of the minimum at 210 nm to 202 nm, indicating a change in the secondary
structure upon incubation (Fig. 6C). Conversely, the CD spectrum of EC1 did not change
after incubation for 28 days (data not shown). In general, the melting curve profiles of EC1-
IN were different from those of EC1 at different days. Although it was not dramatic, the
melting curves of both EC1-IN and EC1 showed some change after 28 days of incubation
(Fig. 7C).
Thermal unfolding properties of EC1-PEG—To evaluate the effect of PEGylation in
EC1, thermal unfolding profiles from 10 °C to 65 °C of EC1-PEG were compared to that of
EC1 at pH 3.0, 7.0, and 9.0 (Fig. 8). The data obtained for the thermal unfolding transitions
were fitted to a sigmoidal function, and the mid-point of each fit was defined as the thermal
unfolding temperature (Tm). The Tm values of EC1-PEG and EC1 at various pH values were
compared. It is clear that the EC1-PEG has a higher Tm than EC1 at all pH values studied,
indicating that alkylation of EC1 with PEG group improves the thermal stability of EC1.
Both proteins have the highest Tm value at pH 7.0.
Tertiary structure properties of EC1-IN and EC1-PEG—The shift in the intrinsic
fluorescence emission maximum was monitored to evaluate changes in the
microenvironment of the Trp6 and Trp66 residues in the EC1-IN, EC1-PEG, and EC1
proteins upon incubation at 4 °C in pH 3.0, 7.0, and 9.0 for 28 days (Table 1). The Trp
emission profiles can provide an indication of the buried or exposed nature of the Trp
residues as well as the tertiary structural properties of the protein. At pH 3.0, a blue shift (3.0
nm) was observed in the emission spectra of EC1 between day 0 to day 28, and this blue
shift suggests the possibility burial of Trp residues in an apolar environment due to protein
aggregation. In contrast, the blue shift in EC1-IN was smaller (0.7 nm) than that in EC1 at
pH 3.0. At pH 7.0, a large red shift (6 nm) was observed in the EC1 spectra, and only a
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small blue shift (~1.0 nm) was observed in EC1-IN spectra after 28 days incubation. The red
shift indicates the exposure the Trp residue(s) to the solvent upon unfolding. Only a small
shift was observed for emission maxima (~1.0 nm) for both EC1 and EC-IN upon incubation
for 28 days at pH 9.0. Using the maximum intensity against temperature, thermal unfolding
curves of EC1-IN and EC1 were obtained upon incubation for 0 and 28 days at 4 °C and pH
7.0. EC1 had one transition around 35 °C on day 0, but displayed two transitions after
incubation for 28 days with the first transition at 35 °C and the second at above 60 °C with a
shift to very high wavelengths (>375 nm). Overall, the fluorescence data obtained suggest
that at pH 3.0, 7.0 and 9.0, the microclimate of the Trp residues in EC1-IN does not change
significantly upon incubation for 28 days at 4 °C. In contrast, emission spectra of EC1 at pH
3.0 and 7.0 and its thermal unfolding at pH 7.0 showed significant changes under the same
incubation conditions.
Intrinsic fluorescence emission spectra of EC1-PEG between 305 nm and 405 nm after
excitation at 295 nm were compared to the EC1 spectra at pH 3.0, 7.0, and 9.0 (Table 1).
The wavelength of maximum emission at pH 3.0 was 339.87 ± 0.03 nm for EC1-PEG,
similar to that for EC1 (339.93 ± 0.04 nm) at pH 3.0. At pH 7.0, it was 339.83 ± 0.05 nm,
similar to that of EC1 (339.27 ± 0.03 nm) at pH 7.0. At pH 9.0, however, there was a small
but significant difference in the wavelengths of maximum emission of EC1-PEG (339.97 ±
0.02 nm) and EC1 (341.31 ± 0.03 nm). A possible explanation for this difference at pH 9.0
is that the PEG interacts with at least one of the two Trp residues, probably the Trp6 residue
that is near the site of PEGylation at the Cys13 residue. The presence of the bulky PEG
group near the Cys13 residue makes Trp6 less exposed to the solvent in EC1-PEG than in
EC1.
DISCUSSION
Our long-term goal is to understand the in vitro and in vivo biological functions of the EC1
domain in inhibiting homotypic and heterotypic cell-cell adhesion. Because of the instability
of EC1, it is necessary to find a method for stabilizing it for its long-term use in biological
assays. One way to prevent the aggregation/precipitation of EC1 is by inhibiting the
covalent dimerization of EC1 via the Cys13 residue (Makagiansar et al., 2002b). The X-ray
structure of EC1 shows that the Cys13 residue is exposed on the surface of EC1 (Nagar et
al., 1996); it is adjacent to Trp6, which can cause domain swapping between two EC1
molecules to form a physical dimer (Pokutta et al., 2008). Molecular modeling studies
indicate that the formation of a covalent dimer of EC1 (EC1-ss-EC1) is a facile reaction
(Makagiansar et al., 2002b). We have shown that the formation of EC1-ss-EC1 dimer
increases the dynamic properties of the EC1 unit compared to the EC1 monomer (Trivedi et
al., 2009). The dynamic nature of EC1-ss-EC1 may contribute to its susceptibility to peptide
bond hydrolysis and aggregation reactions. Thus, alkylation of the Cys13 residue could
prevent intermolecular disulfide bond formation that leads to aggregation of EC1.
Here, we have demonstrated that the thiol group of Cys13 can be modified to a thioether by
alkylation reaction with iodoacetate, iodoacetamide, and maleimide-PEG to generate EC1-
IA, EC-IN, and EC1-PEG, respectively. The PEG group was conjugated via nucleophilic
attack of the maleimide group by the thiol of the Cys13 residue on EC1 to produce EC1-
PEG. This reaction produced the PEGylated product with a single site of modification as
determined by HPLC and mass spectrometry. Although the Cys13 residue is exposed on the
surface of EC1, the alkylation reaction of the thiol group of the folded form of EC1 was
slow; the reaction was accelerated by partially unfolding the protein by incubation in 4.0 M
Gdn.HCl solution. Gradient removal of Gdn.HCl refolded the EC1-IN and EC1-PEG
properly to provide a structure similar to that of the parent EC1 protein as determined by
CD. Unfortunately, while EC1-IA was successfully synthesized, it did not refold properly.
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Therefore, EC1-IA was not investigated further for stability studies. The additional negative
charge on the acetate group of EC1-IA may prevent its proper refolding due to
destabilization of the refolding intermediate via repulsion of negative charges or stabilizing
the undesirable intermediate via charge-charge interactions (i.e. salt bridge). A similar result
has been observed in the derivatization of sorghum phosphoenolpyruvate carboxylase
(PEPC) mutant with iodoacetate; the derivatized product has decreased enzymatic activity
(Duff et al., 1993). In contrast, its derivatization with iodoacetamide did not change the
enzymatic activity of the enzyme (Duff et al., 1993). This result suggests that this difference
in enzymatic activity can be attributed to the introduction of a negative charge in PEPC upon
iodoacetate derivatization but no additional negative charge when derivatized with
iodoacetamide.
Although EC-IN has a CD spectrum similar to that of EC1 at pH 7.0, the CD spectra of
EC1-IN are sensitive to pH changes. At pH 7.0, the EC1-IN has estimated secondary
structure content similar to that of EC1 from the CD spectra; EC1-IN has 47% β-sheet, 5%
α-helix, and 48% random coil and EC1 has 51% β-sheet, 2% α-helix, and 47% random coil.
On the other hand, the CD spectra of EC1-IN were dramatically different from those of the
EC1 protein at pH 3.0 and 9.0. The sensitivity of EC1-IN to pH changes could be due to the
different electronic properties and hydrogen bonding potential of the amide group of
derivatized Cys13 on EC1-IN compared to the parent thiol group of Cys13 on the EC1
protein. The thiol group of Cys13 in EC1 can be ionized to thiolate ion (pKa around 9.1) and
it can form electrostatic interactions with surrounding functional groups. In contrast, the
amide group of the derivatized Cys13 cannot be ionized and may not form efficient
interactions with surrounding functional groups. As noted previously, the thiol group of
Cys13 was not very reactive in the folded form of EC1 and this thiol group could only be
derivatized in the unfolded form. This observation suggests that the thiol group of Cys13 is
involved in hydrogen bonding and/or electrostatic interactions with surrounding functional
groups to stabilize EC1 tertiary structure. Altered secondary structures of proteins upon
derivatization have been observed previously in thiol-alkylated ovalbumin using iodoacetate
and iodoacetamide. The alkylated ovalbumin and BSA have a decreased α-helical content
and an increased β-sheet content (Batra et al., 1989a, b).
The stability of EC1-IN and EC1 monitored by CD and fluorescence indicates that EC1-IN
is more stable than EC1 under pH 3.0 and 4 °C for 14 days. The fluorescence emission
spectra of EC1-IN did not change upon incubation for 28 days at 4 °C, but there was a blue
shift in the emission spectra of EC1 upon treatment under the same condition. The melting
temperatures (Tm) of EC1-IN estimated from CD spectra at both pH 3.0 and 9.0 are higher
than the Tm of EC1. For example, the Tm of EC1-IN is 39.9 ± 1.0 °C, whereas the Tm of
EC1 is 28.8 ± 0.3 °C at pH 3.0. At pH 7.0, however, the Tm of EC1-IN (33.9 ± 0.7 °C) is
lower than the Tm of EC1 (42.0 ± 0.6 °C). A decrease in thermal stability has been reported
previously upon Cys residue alkylation of alpha-alpha tropomyosin (AAT) (Holtzer et al.,
1990). It is interesting to find that although EC1-IN has a lower Tm than EC1 at pH 7.0,
incubation of EC1-IN at 4 °C for 28 days did not result in any change in CD spectra. This is
in contrast to incubation of EC1 under the same conditions, which produced different CD
spectra due to aggregation (Trivedi et al., 2009). These results also support the idea that the
presence of the free thiol group in EC1 catalyzed its instability by forming a covalent dimer,
and the prevention of covalent dimerization inhibited the formation of protein aggregates
and precipitates. Therefore, the Tm alone may not be sufficient for determining the
instability of a protein.
Because EC1-IN has different conformations than the parent EC1 at pH 3.0 and 9.0 and also
has a lower Tm than the parent EC1 at pH 7.0, an alternative alkylation method such as
PEGylation was utilized to improve the stability of EC1 (Morar et al., 2006). In this case,
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the thiol group of the Cys13 residue was reacted with maleimide polyethylene glycol (PEG)
to make EC1-PEG, and its structural characteristics were evaluated using spectroscopic
methods. PEGylation of the Cys residues of proteins has been employed previously to
improve protein in vitro and in vivo stabilities (Bell et al., 2008; Colonna et al., 2008; Long
et al., 2006; Rosendahl et al., 2005a; Rosendahl et al., 2005b; Tsutsumi et al., 2000;
Vanwetswinkel et al., 2000). PEGylation also does not change the protein secondary
structure compared to that of the parent protein (Digilio et al., 2003; Hinds and Kim, 2002).
Far UV CD studies showed some minor differences between CD spectra of EC1-PEG and
EC1 at pH 3.0. At pH 7.0 and 9.0, however, no substantial differences were observed
between the CD spectra of EC1-PEG and EC1. Compared to EC1-IN, the secondary
structure of EC1-PEG is less sensitive to pH changes. The thermal unfolding profiles
determined by CD spectroscopy suggest that EC1-PEG is significantly more stable than
EC1; the increases in Tm of EC1-PEG compared to EC1 are 5.1 °C at pH 3.0, 4.0 °C at pH
7.0, and 7.7 °C at pH 9.0 (Fig. 8). A similar trend was observed by plotting the change in
fluorescence wavelength maximum as a function of temperature. The EC1-PEG protein was
more stable than EC1-IN or EC1 after incubation for 4 h at 70 °C at all three different pH
values (3.0, 7.0. and 9.0). EC1-IN was more stable than EC1 at pH 7.0 and 9.0, but both
proteins were equally unstable at pH 3.0. As with EC1 at pH 3.0 and 70 °C, EC1-IN was
chemically degraded via peptide bond hydrolysis at Asp93–Pro94, and only 22% of EC1-IN
remained in solution after 4-h incubation. Only 10% of the hydrolysis product was observed
in solution because the degradation involved precipitation of the protein. All the methods
examined so far indicate that PEGylation is the best strategy for stabilizing the EC1 protein.
It is also possible that the PEGylation of EC1 decreases the dynamic properties of EC1-
PEG, which contributes to the decrease in the hydrolysis reaction; however, this proposal
needs further investigation.
PEGylation of therapeutic proteins has been shown to improve their physical and biological
properties. PEGylated proteins have a larger hydrodynamic radius with lower glomerular
filtration, lower immunogenicity, and a higher enzymatic stability compared to the parent
protein. It was proposed that PEGylation at several sites on a protein with higher molecular
weight branched PEGs as opposed to linear PEG can form a polymer shell around the
protein; this recruits water to form an outer water shell that minimizes intermolecular protein
interactions (Long et al., 2006; Morar et al., 2006; Rosendahl et al., 2005a; Rosendahl et al.,
2005b; Tsutsumi et al., 2000; Vanwetswinkel et al., 2000). Thus, PEGylation of therapeutic
proteins produces a higher protein systemic circulation, and the amount and frequency of
dosing can be reduced. In EC1-PEG, the PEG group may not be large enough to form a shell
around the entire EC1 molecule because it is a linear 5,000 Da PEG. The X-ray structure of
EC1 shows that the Trp6 and Cys13 residues are located at the dimerization surface. The X-
ray structure of EC1 of C-cadherin shows that the equivalent Trp residue is involved in
domain swapping between two EC1 domains. In other words, the Trp residue on one EC1 is
buried in a hydrophobic pocket of another EC1 to form a physical dimer (Boggon et al.,
2002). It has been suggested that EC1 could have two homophilic binding surfaces, one at
the domain-swapping region at the N-terminal and the other in the region where the His-
Ala-Val (HAV) and Ala-Asp-Thr (ADT) sequences are located (Makagiansar et al., 2001;
Sinaga et al., 2002). Thus, we propose that the presence of the PEG on EC1-PEG near the
domain-swapping region may prevent the formation of physical and chemical dimers of EC1
of E-cadherin. However, the presence of PEG group Cys-13 may not interfere with HAV
region of EC1-PEG for binding to E-cadherin molecules on the cell surface to block cell-cell
adhesion. In addition, EC1-PEG can be used to elucidate the role of the surface opposite to
the PEGylation surface (HAV and ADT surface) on E-cadherin in mediating homophilic and
heterophilic cell-cell adhesion (Kiptoo et al., 2011; Kobayashi et al., 2006; Makagiansar et
al., 2001; Sinaga et al., 2002). It is not yet clear whether the size of PEG molecules can
influence the stability and bioactivity of the EC1-PEG protein. However, the increase in size
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of PEG molecules can increase the vivo systemic circulation of PEGylated protein; this is
presumably due to the increase of the hydrodynamic radius of the PEGylated protein.
In conclusion, alkylation of the Cys residue in EC1 improves the stability of the EC1
domain, indicating that the formation of a covalent dimer of EC1 is crucial for the instability
of EC1. The EC1-PEG is the best modification for improving chemical and physical
stability and long-term storage of EC1. Unlike the modified EC1-IN protein, EC1-PEG has a
structure similar to that of the parent EC1 at different pH values. In the future, the biological
activity of EC1-PEG will be compared to that of EC1-IN and EC1 in inhibiting E-cadherin-
mediated homotypic and heterotypic cell-cell adhesion in in vitro cell culture systems
developed in our laboratory (Kobayashi et al., 2006).
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The alkylation reaction of the thiol group on the Cys13 residue of EC1 with iodoacetate and
iodoacetamide produces the EC1 derivatives EC1-IA and EC1-IN, respectively. The
alkylation of the thiol group with maleimide-PEG-5000 generates EC1-PEG molecule.
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The CD spectra of EC1-IN in buffered solutions at pH 3.0, 7.0, and 9.0. The secondary
structure of EC1-IN is affected by the pH of the solution.
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Comparisons of the secondary structures of EC1 and EC1-PEG using far UV CD at pH: (A)
3.0, (B) 7.0, and (C) 9.0. The spectrum of EC1-PEG is slightly different than that of EC1 at
pH 3.0. However, the CD spectra of EC1-PEG at pH 7.0 and 9.0 are similar to those from
EC1, suggesting that EC1-PEG and EC1 have similar secondary structures at pH 7.0 and
9.0.
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The chemical stability profiles of EC1-IN after incubation for 4 h at pH 3.0, 7.0, and 9.0 at:
(A) 37 °C and (B) 70 °C. At 37 °C, EC1-IN does not undergo any chemical degradation or
precipitation reaction at pH 3.0, 7.0, or 9.0. At 70 °C, EC1-IN shows no peptide bond
hydrolysis or precipitation at pH 7.0 or 9.0; however, EC1-IN undergoes peptide bond
hydrolysis as well as precipitation at pH 3.0. The product of hydrolysis was identified as the
N-terminal fragment G1–D93, a product of hydrolysis at the D93–P94 peptide bond.
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A comparison of the chemical stability of EC1, EC1-IN, and EC1-PEG at pH 3.0, 7.0, and
9.0 after 4-h incubation at 70 °C. It is clear that EC1-PEG is the most stable molecule at all
pH values. EC-IN is stable at pH 7.0 and 9.0 but not at pH 3.0. EC1 is the least stable
molecule at all pH values compared to EC1-PEG and EC1-IN.
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(A) Comparison of the CD spectra of EC1-IN and EC1 after their incubation at pH 3.0 for
14 days at 4 °C. The CD spectrum of EC1-IN does not change substantially after 14 days,
whereas the spectrum of EC1 changes upon 14 days incubation. (B) The CD spectra of EC1-
IN after its incubation at pH 7.0 for 14 and 28 days at 4 °C. The CD spectrum of EC1-IN
does not change substantially after 14 and 28 days. (C) The CD spectra of EC1-IN after
incubation at pH 9.0 for 14 and 28 days at 4 °C. The CD spectra of EC1-IN after 14 and 28
days are substantially different from those on day 0.
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Comparison of the thermal unfolding curves of EC1-IN and EC1 proteins after incubation
for 14 days at (A) pH 3.0, (B) pH 7.0, and (C) pH 9.0. There is a very small difference in the
thermal unfolding curves of EC1-IN, whereas a clear change is seen in the thermal unfolding
curve of EC1. The inset shows that the thermal unfolding curves of EC1-IN can be fitted to
sigmoidal functions. Thermal unfolding profile of EC1 and EC1-IN measured by the CD
signal at 218 nm after incubation for 0, 14, and 28 days at 4 °C at pH 7.0. There are limited
differences in the thermal unfolding curves of EC1-IN, but dramatic differences are seen in
the thermal unfolding curves of EC1. EC1 has a higher transition temperature than EC1-IN,
indicating that EC1-IN is less stable to thermal unfolding than EC1. Thermal unfolding
profile of EC1 and EC1-IN measured by the CD signal at 218 nm after incubation for 0, 14,
and 28 days at 4 °C and pH 9.0. The thermal unfolding curves of EC1-IN are substantially
different from those of EC1.The inset shows that the thermal unfolding of EC1-IN can be
fitted to sigmoidal functions.
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Thermal unfolding profile of EC1-PEG compared to that of EC1 obtained by plotting the
CD signal at 218 nm against the corresponding temperature at (A) pH 3.0, (B) pH 7.0, and
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(C) pH 9.0. (D) A comparison of the unfolding temperatures (Tms) for EC1-PEG and EC1
at pH 3.0, 7.0, and 9.0 after fitting the CD thermal unfolding profiles to sigmoidal functions.
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Table 1
The wavelength at the maximum intensity fluorescence emission
EC1 (λ in nm) EC1-IN (λ in nm) EC1-PEG (λ in nm)
pH 3.0
Day 0 339.93 ± 0.04 340.61 ± 0.08 339.87 ± 0.03
Day 28 337.09 ± 0.04 338.91 ± 0.06
pH 7.0
Day 0 339.27 ± 0.03 342.13 ± 0.05 339.83 ± 0.05
Day 28 345.81 ± 0.13 341.21 ± 0.05
pH 9.0
Day 0 342.0 ± 0.0 343.0 ± 1.0 339.97 ± 0.02
Day 28 339.67 ± 1.15 341.67 ± 0.58
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